US judge will allow controversial evidence in Roundup cancer trials

A federal judge overseeing lawsuits alleging Bayer AG’s glyphosate-based Roundup weed killer causes cancer on Monday tentatively allowed pieces of controversial evidence that the company had hoped to exclude from upcoming trials.

U.S. District Judge Vince Chhabria during a hearing in San Francisco federal court called his decision “probably most disappointing for Monsanto,” the Bayer unit that manufactures the world’s most widely used herbicide.

The company denies allegations that glyphosate causes cancer and says decades of independent studies have shown the chemical to be safe for human use.

Chhabria on Monday said plaintiffs could introduce some evidence of Monsanto’s alleged attempts to ghostwrite studies and influence the findings of scientists and regulators during the first phase of upcoming trials. He said documents which showed the company taking a position on the science or a study introduced during the first phase were “super relevant.”

The company had hoped the judge would take a harder line on such evidence following a Jan. 3 order by Chhabria restricting evidence of corporate misconduct. At the time, that decision lifted Bayer’s shares nearly 7 percent.

Monsanto had argued much of this evidence was a “sideshow” that would only distract jurors from the scientific evidence.

Plaintiffs’ lawyers contended some evidence of corporate misconduct was inextricably linked to their scientific claims.

The judge appeared to agree with them, saying it was difficult to draw the line between scientific evidence and allegations of corporate misconduct, and questioned whether it would be fair for the jury to not hear about the company’s alleged attempts to influence scientists.

The parties did agree that other internal documents, including emails of Monsanto employees discussing lobbying efforts, do not belong in the initial trial phase.

Under Chhabria’s order, that evidence would be allowed only if glyphosate was found to have caused plaintiff Edwin Hardeman’s cancer and the trial proceeded to a second phase to determine Bayer’s liability.

The order applies to Hardeman’s case, which is scheduled to go to trial on Feb. 25, and two other upcoming cases. There are some 620 Roundup cases before Chhabria, out of more than 9,300 nationwide.

Plaintiffs’ lawyers believe corporate misconduct evidence was critical to a California state court jury’s August decision to award $289 million in a similar case. The verdict sent Bayer shares tumbling at the time, though the award was later reduced to $78 million and is under appeal.

Reporting by Tina Bellon in New York; Editing by Anthony Lin and Bill Berkrot